Table 1.
Comparison of baseline characteristics in the propensity score-matched sample.
| Sustained virologic response (n = 384) | Chronic infection (n = 768) | Standardized mean difference | |
| Median age (IQR) (years) | 51 (45–55) | 51 (45–55) | 0 |
| Female | 80 (21%) | 169 (22%) | 0.03 |
| African/Caribbean ethnicity | 17 (4%) | 24 (3%) | 0.07 |
| Aboriginal ethnicity | 35 (9%) | 75 (10%) | 0.02 |
| Injection cocaine use | 43 (11%) | 94 (12%) | 0.03 |
| Injection opiate use | 46 (12%) | 90 (12%) | 0.01 |
| Noninjection cocaine use | 61 (16%) | 142 (18%) | 0.07 |
| Noninjection opiate use | 58 (15%) | 128 (17%) | 0.04 |
| Hazardous alcohol consumption | 64 (17%) | 141 (18%) | 0.04 |
| Median current CD4+ count (IQR) (cells/μl) | 530 (360–740) | 530 (330–760) | 0.01 |
| Median nadir CD4+ count (IQR) (cells/μl) | 190 (90–300) | 190 (90–325) | 0.09 |
| Detectable HIV RNA at least 50 copies/ml | 39 (10%) | 72 (9%) | 0.03 |
| Prior AIDS-defining events | 98 (26%) | 226 (29%) | 0.09 |
| Current tenofovir disoproxil fumarate exposure | 223 (58%) | 430 (56%) | 0.04 |
| Ever tenofovir disoproxil fumarate exposure | 267 (70%) | 533 (69%) | 0 |
| Current protease inhibitor exposurea | 112 (29%) | 216 (28%) | 0.02 |
| Ever protease inhibitor exposurea | 178 (46%) | 354 (46%) | 0.01 |
| Median duration of HCV infection (IQR) (years) | 21 (12–30) | 21 (12–29) | 0.02 |
| Hypertension | 57 (15%) | 119 (15%) | 0.02 |
| Diabetes | 28 (7%) | 50 (7%) | 0.03 |
| Liver fibrosis (APRI ≥ 1.5) | 156 (41%) | 348 (45%) | 0.09 |
| Median eGFR (IQR) (ml/min per 1.73 m2) | 91 (74–104) | 91 (74–104) | 0.01 |
| Recent hospitalization in the last 6 months | 41 (11%) | 100 (13%) | 0.07 |
Values are n (%), unless otherwise indicated. APRI, aspartate aminotransferase-to-platelet ratio index; eGFR, estimated glomerular filtration rate; HCV, hepatitis C virus; IQR, interquartile range.
aLopinavir/ritonavir or atazanavir, with or without ritonavir.